Clinical trial NCT03437941: Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Official title: Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Metastatic Castration-Resistant Prostate Cancer
Keywords: Prostate Cancer
Castration-Resistant Prostate Cancer
Glucocorticoid receptor
Antagonist
mCRPC
enzalutamide
androgen receptor
Lead sponsor: Corcept Therapeutics
Sponsor class: INDUSTRY
First posted: 2018-02-19
Enrollment: 39
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open-label, Phase 1/2a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and preliminary efficacy of CORT125281 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2 studies.

Detailed description: CORT125281 is a selective glucocorticoid receptor (GR) antagonist. In this study, CORT125281 will be administered orally in combination with enzalutamide to patients with metastatic castration-resistant prostate cancer (mCRPC) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the regimen. The study consists of two phases: a dose-determination phase and an expansion phase. The dose determination phase is designed to determine dose-limiting toxicities and the RD of CORT125281 plus enzalutamide in patients with mCRPC. Once the recommended dosing regimen has been determined, the following expansion cohorts will be enrolled and treated with CORT125281 plus enzalutamide at the recommended dose level.

Abi-Resistant Cohort: Patients who have progressed during treatment with abiraterone, and have received no other androgen receptor (AR)-blocking therapies

ARant-Resistant Cohort: Patients who have progressed during treatment with enzalutamide or other second-generation AR inhibitors.

The effect of food on CORT125281 PK will be assessed in a portion of the patients enrolled in the Expansion Phase. The two expansion cohorts will be enrolled in parallel.

In each phase of the study, routine assessments of safety and tolerability will be performed and samples will be collected to determine standard PK parameters for CORT125281, enzalutamide, and their major metabolites. PD, quality of life evaluations and preliminary evaluations of anti-tumor activity of CORT125281 with enzalutamide will be performed throughout the study.

Eligibility criteria: Major Inclusion Criteria:

* Able to understand the purpose and risks of the study; willing and able to adhere to scheduled visits, treatment plans, laboratory tests, and other study evaluations and procedures, and provide written informed consent
* Males ≥18 years of age at the time of signing consent
* Histologically confirmed adenocarcinoma of the prostate with metastatic disease
* Dose-Determination Phase Segment 1 and Expansion Phase: Progressive disease as defined by PSA or imaging after most recent prior therapy. PSA ≥1 ng/mL, if a confirmed rise in PSA is the only indication of progression. Progression by PSA requires rising PSA over a previous reference value by at least 2 measurements obtained ≥1 week apart. PSA measurements can be collected during or after the most recent prior therapy.
* Dose-Determination Phase Segment 2: Currently receiving enzalutamide with a rising PSA as follows:

  1. Rising PSA: 25% increase over nadir and an absolute value of \>1 ng/mL by at least 2 measurements obtained ≥1 week apart. PSA measurements can be collected during or after the most recent prior therapy.
  2. Patients must have received enzalutamide for a minimum of 12 weeks and be on stable doses of enzalutamide ≥80 mg QD for at least 4 weeks prior to Cycle 1 Day 1. Patients will continue enzalutamide without interruption during the Screening Period (no wash-out period). This will be the enzalutamide starting dose for combination with CORT125281 beginning on Cycle 1 Day 1.
  3. M0 disease is allowed
* Expansion Phase: Patients must have progressed while receiving an androgen-directed therapy as follows:

  1. Abi-Resistant Cohort: Patients must have progressed during treatment with abiraterone.
  2. ARant-Resistant Cohort: Patients must have progressed during treatment with enzalutamide or second-generation AR-blocking therapies. Patients progressing on enzalutamide immediately prior to enrolling in this study must be on stable doses of enzalutamide. These patients will continue enzalutamide without interruption during the Screening Period (no wash-out period required).
* Baseline tumor assessment performed within 28 days prior to the first dose of study treatment (CORT125281 and/or on-study enzalutamide, whichever is earliest)
* Prior surgical or chemical castration with serum testosterone \<1.7 nmol/L (50 ng/dL). If the method of castration is use of a luteinizing hormone releasing hormone (LHRH) analogue,there must be a plan to maintain effective LHRH analogue treatment for the duration of the trial
* Consent to have all protocol required pharmacodynamic biomarker samples, including the pretreatment and on treatment paired tumor biopsies (mandatory for a subset of patients).
* Consent to provide mandatory pharmacogenomic blood sample (Dose-Determination Segment 1 only)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate baseline organ function within 14 days prior to the first dose of study treatment (on-study enzalutamide and/or CORT125281, whichever is earliest)
* Patients receiving systemic corticosteroids greater than 2-weeks in duration within 3 months of study entry or with clinical evidence of adrenal insufficiency must have evidence of adequate adrenal function based upon morning plasma cortisol concentration or ACTH (cosyntropin) stimulation test
* If a patient engages in sexual intercourse with a woman of childbearing potential, a condom with spermicide and another form of birth control must be used during and for 100 days after the final dose of study treatment (CORT125281 or enzalutamide, whichever is latest). A condom is required during and for 100 days after completing treatment with enzalutamide if a patient is engaged in sexual activity with a pregnant woman. Patients must also agree to avoid sperm donation during the study and for at least 100 days after the final treatment administration.

Major Exclusion Criteria:

* Received chemotherapy, non-palliative radiotherapy, immunotherapy, or any investigational cancer therapies within 21 days prior to the first dose of CORT125281, or treatment with such therapies is planned during protocol treatment. Concomitant anticancer therapy is not permitted during the enzalutamide Lead-in Period during Dose-Determination Phase Segment 1
* More than two prior cytotoxic chemotherapy regimens for the treatment of mCRPC

Dose Determination Phase and Expansion Phases will exclude patients for the following:

* Dose-Determination Phase (Segment 1 only)
* Progressed during treatment with enzalutamide prior to Cycle 1 Day -28 (only applies to patients receiving enzalutamide Lead-in) or
* Received prior 2nd generation anti-androgen and require urgent disease response or stabilization
* Expansion Phase Abi-Resistant Cohort:

  * Received prior treatment with enzalutamide, or
  * Received prior 2nd generation anti-androgen and require urgent disease response or stabilization
* Expansion Phase ARant-Resistant Cohort: Require urgent disease response or stabilization
* Ongoing or anticipated therapy with hormone therapy (other than LHRH analogue), including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart) or received abiraterone within 28 days prior to the first dose of CORT125281
* Contraindication or precaution for enzalutamide
* Parenchymal brain metastases
* Any clinically significant uncontrolled condition that may increase the risk to the study patient or that the Investigator considers places the patient at unacceptable risk
* Received herbal products or alternative therapies that may decrease PSA levels or that may have hormonal anti-prostate cancer activity (e.g., saw palmetto, PC-SPES, PC- HOPE, St. John's wort, selenium supplements, grape seed extract, etc.) within 28 days of study treatment initiation or plans to initiate treatment with these products/alternative therapies during the entire duration of the study
* Received systemic glucocorticoids within 21 days prior to the first dose of CORT125281, or requirement for chronic or frequently used systemic or inhaled glucocorticoids for medical conditions (e.g., rheumatoid arthritis, immunosuppression after organ transplantation). Short courses (\<5 days) for non-cancer related reasons are allowed if clinically required (such as prophylaxis for CT).
* Concurrent therapy with strong inhibitors or inducers of CYP3A4 or CYP2C8 or with sensitive substrates of CYP3A4, CYP2C9 or CYP2C19

Primary outcomes:
measure: Maximum Tolerated Dose
timeFrame: 10 months
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: 24 months
measure: AUC 0-last Pharmacokinetic (PK) parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: AUC 0-24hr PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: AUC 0-infinity PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: Cmax PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: Cmin,ss PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: CL/F PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: Tmax PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: λz PK parameter
timeFrame: Cycle 1 Day 1 through Cycle 3 Day 1
measure: Effect of food on the Cmax PK of CORT125281
timeFrame: Cycle 1 Day -7
measure: Effect of food on the AUC0-t PK of CORT125281
timeFrame: Cycle 1 Day -7
measure: Effect of food on the AUCinf PK of CORT125281
timeFrame: Cycle 1 Day -7
measure: Objective Response Rate (ORR)
timeFrame: 12 months from the enrollment of the final subject
measure: Reduction in prostate-specific antigen (PSA)
timeFrame: 12 months from the enrollment of the final subject
measure: Time to symptomatic skeletal event (SSE)
timeFrame: 12 months from the enrollment of the final subject
measure: Radiographic progression-free survival (rPFS)
timeFrame: Baseline to 12 months
measure: Time to prostate-specific antigen (PSA) progression
timeFrame: Baseline to 12 months
measure: Time to clinical progression
timeFrame: Baseline to 12 months
measure: Duration of Response (DOR)
timeFrame: 12 months from the enrollment of the final subject
measure: Overall Survival (OS)
timeFrame: 12 months from the enrollment of the final subject
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Scottsdale
state: Arizona
city: Detroit
country: United States
facility: Detroit
state: Michigan
city: New York
country: United States
facility: New York
state: New York
city: Portland
country: United States
facility: Portland
state: Oregon
city: Madison
country: United States
facility: Madison
state: Wisconsin
city: London
country: United Kingdom
facility: London
state: England
city: Southampton
country: United Kingdom
facility: Southampton
state: England
city: Sutton
country: United Kingdom
facility: Sutton
state: Surrey
Study officials:
affiliation: Corcept Therapeutics
name: William Guyer, PharmD
role: STUDY_DIRECTOR
affiliation: Corcept Therapeutics
name: Grace Mann, PhD
role: STUDY_DIRECTOR
References:
citation: Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 Apr 14;28(8):1549-1559. doi: 10.1158/1078-0432.CCR-21-4049.